Friday, January 11, 2019 3:34:46 PM
The beginning of a Stat article (nothing much more of note in this short article):
“Amarin’s CEO drops enough JPM19 hints to know Vascepa sales driving higher
By ADAM FEUERSTEIN @adamfeuerstein JANUARY 9, 2019
ALEX HOGAN/STAT
SAN FRANCISCO — Amarin (AMRN) CEO John Thero used his Wednesday breakout session at the J.P. Morgan Healthcare Conference to not-so-subtly telegraph a stronger 2019 sales outlook for Vascepa than the company’s official guidance offered last week.
Thero, of course, can’t come out directly and say that Vascepa, Amarin’s heart drug derived from fish oil, will deliver significantly more than a 50 percent year-over-year increase to $350 million in 2019 sales. Like Fight Club, the first rule of sandbagging revenue guidance is not talking about sandbagging revenue guidance.
But during meetings with investors over three days here, and then on Wednesday during the breakout session, Thero dropped plenty of hints. …”
As a bonus, here’s some recent twitter action with AF, raf, and me:
Adam Feuerstein?Verified account @adamfeuerstein 23h23 hours ago
Help me with the logic here: $AMRN CEO John Thero just spent 4 days in SF meeting face to face with investors while ALSO negotiating a $PFE takeout? People, please...
Charles Crosby Lyon? @chas1232123 7h7 hours ago
Help me with the logic here Adam: after rock solid confirmation $AMRN ’s #Vascepa is the biggest #cardiovascular protection breakthrough in several decades, on top of not really reporting that, you now imply either $PFE is uninterested or would be stopped by JPM? Adam, please…
Adam Feuerstein?Verified account @adamfeuerstein 7h7 hours ago
Hi Charles — I can’t cure your stupidity. Apologies.
4 replies 0 retweets 4 likes
ra fun? @ra_fun
Replying to @adamfeuerstein @chas1232123
Poor little Adam has had his feelings hurt too many times, he has been on the wrong side of Amarin too many times.
Charles Crosby Lyon? @chas1232123 6h6 hours ago
Thanks for taking time to respond. Still want help with your logic. My engineering degrees and extensive DD led me to facts about #Vascepa and $AMRN I summarized here, with a deep dive on placebo: Seeking Alpha article on AMRN facts Why do you think Dr. Bhatt and I and many more are wrong?
PantherFan? @PickingMyOwn 6h6 hours ago
Replying to @adamfeuerstein @chas1232123
Charles I sometimes get irritated at AF too but I don't get what you are on him about? He's a fan of $AMRN and thinks a B/O makes sense. He is skeptical that JT was engaged in negotiating in SF. So why is that offensive?
1 reply 0 retweets 2 likes
Charles Crosby Lyon? @chas1232123 2h2 hours ago
If $PFE doesn’t buy $AMRN, it won’t be because of JPM. AF downplayed #AMRN ‘s confirmed #Vascepa breakthrough, severely over-stressing very minor placebo concerns. Understandable error, but instead of correcting he endorsed the indefensible Herper hit piece, and more jabs.
AF has a poli-sci degree. I'm guessing the poli doesn't stand for polite, and the sci doesn't have much to do with real science.
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM